MedTrace Logo

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

NCT07021066 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-04-30

No results posted yet for this study

Summary

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.

Conditions

  • Gastric Adenocarcinoma
  • Advanced Pancreatic Ductal Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Biliary Tract Cancer
  • Other Solid Tumors

Interventions

DRUG

BL-M05D1

BL-M05D1 will be administered on D1 every 3 weeks.

Sponsors & Collaborators

  • SystImmune Inc.

    lead INDUSTRY

Principal Investigators

  • Sarah Tannenbaum · SystImmune Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-30
Primary Completion
2027-02-28
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07021066 on ClinicalTrials.gov